Loading…
Clinical-stage biotech developing long-acting antibody drugs for inflammatory bowel disease.
Clinical-stage biotech developing long-acting antibody drugs for inflammatory bowel disease.
Moat: none (IP / patents). Pre-commercial with no approved products yet; differentiation rests on longer-acting antibody engineering.
Headquarters: Waltham, Massachusetts, United States · Founded: 2022 · Employees: 102
Size Spyre Therapeutics (SYRE) is a United States Health Care company (Pharmaceuticals: Major) with a market value of $9.86B, the 785th largest of 3,117 United States companies the cockpit tracks. Shares closed at $103.86 on 6 Nov 2026.
Performance Over six months the shares gained 38.4%, against +4.6% for the median peer and -1.1% for the United States market (cap-weighted) — 6th highest of 21 in its peer set.
Short interest Short interest is 13.6% of the free float (15 Oct 2026).
Next results Next results expected around 4 Mar 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $886,000 | $2.33M |
| Revenue growth | — | — | -100% | -62% | — |
| Gross profit | $0 | $0 | $0 | -$78,000 | $365,000 |
| EBITDA | -$320M | -$220M | -$209M | -$117M | -$82.8M |
| Net income | -$253M | -$127M | -$150M | -$94.9M | -$83.8M |
| Free cash flow | n/a | n/a | -$158M | -$99.9M | -$80.2M |
| Capital expenditure | $0 | $0 | $0 | $0 | $38,000 |
| Total debt | $0 | $0 | $0 | $84.6M | $4.64M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Spyre Therapeutics SYRE | $9.86B | +38% | n/a | n/a | n/a | n/a |
| AbbVie ABBV | $515B | +45% | +11% | 36% | 8.9× | -0.1% |
| Johnson & Johnson JNJ | $665B | +26% | +8% | 26% | 7.0× | 3.5% |
| Pfizer PFE | $168B | +14% | +1% | 26% | 3.4× | -4.3% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | SYRE | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +30.0% | +4.7% | highest of 21 |
| 6-month return | +38.4% | +4.6% | 6th highest of 21 |
| Distance from 52-week high | -5.7% | -14.9% | 5th highest of 21 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Spyre Therapeutics SYRE | United States | $9.86B | +38% | n/a | n/a | n/a | n/a | n/a |
| Akeso 9926.HK | Hong Kong | $10.2B | -38% | +42% | -25% | 19.5× | n/a | n/a |
| Madrigal Pharmaceuticals MDGL | United States | $9.28B | -22% | +93% | -11% | 6.1× | n/a | n/a |
| TG Therapeutics TGTX | United States | $9.16B | +40% | +76% | 17% | 11.7× | 50.3% | +426.7% |
| ImmunityBio IBRX | United States | $9.15B | +1% | +193% | -152% | 60.5× | n/a | n/a |
| Mankind Pharma MANKIND.NS | India | $11.1B | +7% | +13% | 21% | 7.0× | 27.6% | +18.1% |
| Repligen RGEN | United States | $11.1B | +41% | +14% | 9% | 13.6× | 56.4% | +15.0% |
| Shanghai Fosun Pharmaceutical (Group) 600196.SS | China | $8.70B | -5% | +8% | 6% | 2.3× | 4.1% | +6.6% |
| Pharmaron Beijing 300759.SZ | China | $11.3B | +57% | +18% | 14% | 5.0× | n/a | n/a |
| Protagonist Therapeutics PTGX | United States | $8.54B | +33% | +35% | 21% | 27.6× | 47.5% | +10.0% |
| Shanghai Pharmaceuticals 2607.HK | Hong Kong | $8.48B | -7% | +9% | 3% | 0.3× | -10.3% | +7.4% |
| Asymchem Laboratories (Tianjin) 6821.HK | Hong Kong | $8.19B | +22% | +24% | 17% | 6.8× | n/a | n/a |
| ALK-abello A/S ALK-B.CO | Denmark | $8.14B | -5% | +17% | 27% | 7.8× | 7.6% | +12.6% |
| Kyowa Kirin 4151.T | Japan | $8.05B | +4% | +10% | 24% | 2.0× | -6.1% | +9.3% |
| Dr. Reddy's Laboratories DRREDDY.NS | India | $12.1B | +5% | -4% | 9% | 3.5× | 30.1% | +12.1% |
| H. Lundbeck A/S HLUN-A.CO | Denmark | $8.02B | +47% | +9% | 27% | 2.4× | -9.1% | +6.6% |
| Corcept Therapeutics CORT | United States | $7.96B | +39% | +30% | 12% | 7.9× | 24.9% | +16.6% |
| Zhangzhou Pientzehuang Pharmaceutical 600436.SS | China | $12.3B | -5% | -19% | 19% | 10.3× | 25.8% | +6.8% |
| Recordati REC.MI | Italy | $12.3B | +3% | +9% | 30% | 4.8× | 1.9% | +12.6% |
| Rhythm Pharmaceuticals RYTM | United States | $7.78B | +19% | +61% | -67% | 27.4× | n/a | n/a |
| Praxis Precision Medicines PRAX | United States | $7.75B | -16% | -100% | n/a | n/a | n/a | n/a |